Biomarin Pharmaceutical reported $389.06M in Gross Profit on Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US USD 128.58M 3.32M
Agios Pharmaceuticals AGIO:US USD 3M 2.15M
Alnylam Pharmaceuticals ALNY:US USD 223.19M 39.18M
Amgen AMGN:US USD 5.09B 28M
Bayer BAYN:GR EUR 7.03B 105M
Biogen BIIB:US USD 2.04B 66.1M
Biomarin Pharmaceutical BMRN:US USD 389.06M 21.62M
Bluebird Bio BLUE:US USD 71K 297K
Gilead Sciences GILD:US USD 5.99B 346M
Insmed INSM:US USD 54.26M 5.43M
Intercept Pharmaceuticals ICPT:US USD 77.16M 5.72M
Moderna Inc MRNA:US USD 2.26B 1.1B
Ptc Therapeutics PTCT:US USD 203.12M 47.23M
Regeneron Pharmaceuticals REGN:US USD 2.87B 255.4M
Roche Holding ROG:VX 22.73B 924M
Sarepta Therapeutics SRPT:US USD 190.32M 5.38M
Seattle Genetics SGEN:US USD 402.18M 10.78M
Ultragenyx Pharmaceutical RARE:US USD 82.07M 999K
United Therapeutics UTHR:US USD 478.8M 41.6M